Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Kazuyoshi Kato, Yutaka Takahashi, Makio Shozu
Summary: The study investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer. Results showed that this tailored dosage chemotherapy was effective and well tolerated in these patients.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Environmental Sciences
Anandha Rao Ravula, Suresh Yenugu
Summary: Long-term exposure to pyrethroids affects transgenerational fecundity by influencing changes in sperm proteome, indicating the potential adverse effects of these compounds on reproductive health.
Article
Oncology
Volker Moebus, Hans-Joachim Lueck, Ekkehart Ladda, Peter Klare, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marme, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Jenny Furlanetto, Knut Engels, Christine Solbach, Sabine Schmatloch, Julia Rey, Nicole Burchardi, Sibylle Loibl
Summary: The interim analysis of the GAIN-2 trial showed no difference in invasive disease-free survival between intense dose dense (idd) and tailored dose-dense chemotherapy regimens, but tailoring treatment improved outcomes for patients with HR+/HER2-, lobular cancer, and those aged ≤50 years.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Alphonse Umugire, Youngmi Choi, Sungsu Lee, Hyong-Ho Cho
Summary: Methotrexate (MTX) is widely used in cancer treatment but can cause damage to normal organs and cells. Folinic acid (FA) is an antidote for MTX toxicity. This study investigated the protective effects of the antioxidant Avenanthramide-C (AVN-C) against MTX-induced hearing loss and damage to the ear structures. The results showed that AVN-C preserved hearing and protected against cochlear damage caused by MTX. AVN-C reversed the changes in cell viability and reactive oxygen species (ROS) levels in HEI-OC1 cells treated with MTX. The findings suggest that AVN-C protects against MTX-induced ototoxicity by inhibiting ROS.
Article
Oncology
Rachel D. Harris, Melanie Brooke Bernhardt, Mark C. Zobeck, Olga A. Taylor, Maria Monica Gramatges, Eric S. Schafer, Philip J. Lupo, Karen R. Rabin, Michael E. Scheurer, Austin L. Brown
Summary: This study evaluated risk factors for neurotoxicity after high-dose methotrexate (HD-MTX) therapy in pediatric acute lymphoblastic leukemia (ALL) patients. The researchers found that serum creatinine elevations ≥ 50% may be associated with an increased risk for neurotoxicity among Latino children with ALL.
Article
Food Science & Technology
Dragana Javorac, Simona Tatovic, Milena Andelkovic, Aleksandra Repic, Katarina Baralic, Aleksandra Buha Djordjevic, Marija Mihajlovic, Jelena Kotur Stevuljevic, Danijela Dukic-Cosic, Marijana Curcic, Biljana Antonijevic, Zorica Bulat
Summary: This study aimed to simulate low-level subacute lead exposure and investigate the redox status and metal levels in cardiac tissue of Wistar rats. The results showed that lead can induce oxidative damage in the heart tissue, with increased levels of superoxide anion radical and malondialdehyde. The calculated benchmark dose for malondialdehyde may be useful in assessing the human health risks of low-level lead exposure.
FOOD AND CHEMICAL TOXICOLOGY
(2022)
Article
Medicine, General & Internal
Job P. van Kooten, Michelle Dietz, Niels A. D. Guchelaar, Alexandra R. M. Brandt-Kerkhof, Stijn L. W. Koolen, Jacobus W. A. Burger, Ron H. J. Mathijssen, Cornelis Verhoef, Joachim G. J. Aerts, Eva V. E. Madsen
Summary: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumor, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the only potential curative treatment. However, most patients are not eligible for this treatment, highlighting the need for palliative options. This study aims to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in MPM patients and assess its safety and pharmacokinetics.
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Article
Oncology
Deniz Can Guven, Fatma Gul Gulbahce Incesu, Hasan Cagri Yildirim, Enes Erul, Elvin Chalabiyev, Burak Yasin Aktas, Deniz Yuce, Zafer Arik, Saadettin Kilickap, Sercan Aksoy, Mustafa Erman, Kadir Mutlu Hayran, Serhat Unal, Alpaslan Alp, Omer Dizdar
Summary: This study aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. The results showed that cancer patients had lower antibody levels and seropositivity rates after two doses of CoronaVac compared to the control group. However, the seroconversion rate significantly increased and antibody titers improved after administering a third dose of an mRNA vaccine. Administering a third dose of mRNA vaccine can effectively improve the immunogenicity of CoronaVac in cancer patients receiving active treatment.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C. G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer, Juri Ruf
Summary: This study analyzed the monitoring and estimation methods of kidney dose in prostate cancer patients undergoing radioligand therapy. The results showed that pretherapeutic kidney function is not a reliable predictor of subsequent kidney dose, and individual first-cycle dose estimation is more accurate. The integration of dose information from multiple cycles further improves the prediction.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E. Stinchcombe, Jeffrey D. Bradley, Everett Vokes
Summary: A randomized trial found that 45-Gy twice-daily radiotherapy is still the standard treatment for limited-stage small-cell lung cancer, despite the fact that most patients receive higher-dose once-daily regimens in clinical practice. This study provides the most robust information available to guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ganlu Ouyang, Yanyang Liu, Jiewei Liu, Lin Huang, Feng Luo, Lu Li
Summary: This study aimed to demonstrate the efficacy and safety of reduced-dose chemotherapy plus immunotherapy in lung squamous cell carcinoma (LUSC) patients in the real world. The results showed that the reduced-dose chemotherapy group had similar efficacy and tolerability compared to the standard-dose group, with fewer side effects.
Article
Oncology
Yunqin Liu, Chunbao Zang, Liting Qian, Ailin Wu, Xue Ke
Summary: The study demonstrated that dose-painted intensity-modulated radiotherapy combined with chemotherapy achieved good outcomes for stage IIIB cervical cancer patients, with a 5-year overall survival rate of 61.0% and progression-free survival rate of 55.0%. The cumulative rates of total grade 3 or higher chronic gastrointestinal or genitourinary toxicities were relatively low.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Ke Cao, Josephine Yeung, Yasser Arafat, CheukShan Choi, Matthew Y. K. Wei, Steven Chan, Margaret Lee, Paul N. N. Baird, Justin M. C. Yeung
Summary: This study aims to evaluate the effectiveness of body surface area (BSA), two-dimensional and three-dimensional body composition measurements derived from Lumbar 3 vertebra (L3) computed tomography (CT) slices in predicting dose-limiting toxicities (DLT) in colon cancer patients. The results suggest that compared to BSA and two-dimensional body composition measurements, three-dimensional L3 body composition measurements have greater potential in predicting DLT in CRC patients receiving chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Soenke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Summary: This study aims to investigate whether reduced dose GemNab is superior to full dose Gem in patients with resectable pancreatic cancer. The study will explore various endpoints including progression-free survival, overall survival, overall response rate, quality of life, toxicity, and rate of hospitalizations. The correlation between blood inflammatory markers, circulating tumor DNA, tissue biomarkers, and chemotherapy resistance will also be studied, along with measures of frailty to assess personalized treatment allocation or interventions.
Article
Oncology
A. Matikas, K. Wang, E. Lagoudaki, B. Acs, I Zerdes, J. Hartman, E. Azavedo, J. Bjohle, L. Carlsson, Z. Einbeigi, I Hedenfalk, M. Hellstrom, T. Lekberg, N. Loman, A. Saracco, A. von Wachenfeldt, S. Rotstein, M. Bergqvist, J. Bergh, T. Hatschek, T. Foukakis
Summary: The study highlights the potential value of TK1 activity as a prognostic marker in breast cancer patients. Changes in TK1 activity during chemotherapy were closely associated with patient survival outcomes, improving event-free survival and overall survival rates.
Review
Oncology
Mei-Yin C. Polley, Maura N. Dickler, Jason Sinnwell, Kathleen Tenner, Juan de la Haba, Sibylle Loibl, Matthew P. Goetz, Jonas Bergh, John Roberston, Fergus Couch, Matthew J. Ellis, Miguel Martin
Summary: Endocrine therapy is effective in treating HR+/HER2- advanced breast cancer, but progression is common. A web-based calculator was developed to predict disease outcomes in women with HR+ABC receiving first-line single-agent ET. Factors like number of metastatic sites, measurable disease, age, BMI, PR status, and prior therapy were associated with worse progression-free survival. The models were well-calibrated and showed moderate discrimination ability.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Caroline Boman, Ioannis Zerdes, Kira Martensson, Jonas Bergh, Theodoros Foukakis, Antonios Valachis, Alexios Matikas
Summary: The study found significant discordance in PD-L1 expression between primary and metastatic breast cancer, especially when PD-L1 status is assessed at metastatic sites. Pooled analysis of PD-L1 positivity rates in tumor cells and immune cells showed higher positivity in primary tumors compared to metastasis. Therefore, appropriate tissue sampling is crucial when selecting patients for immunotherapy.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Thomas Hatschek, Theodoros Foukakis, Judith Bjohle, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Ana Bosch, Gyula Pekar, Henrik Lindman, Aglaia Schiza, Zakaria Einbeigi, Jamila Adra, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Susanne Agartz, Edward Azavedo, Per Gryback, Mats Hellstrom, Hemming Johansson, Claudia Maes, Ioannis Zerdes, Johan Hartman, Yvonne Brandberg, Jonas Bergh
Summary: A randomized phase 2 trial in Sweden compared standard neoadjuvant therapy with combination DTP to T-DM1 monotherapy in ERBB2-positive breast cancer patients, showing no significant difference in treatment outcomes between the two groups.
Article
Oncology
R. Bradley, J. Braybrooke, R. Gray, R. K. Hills, Z. Liu, H. Pan, R. Peto, D. Dodwell, P. McGale, C. Taylor, J. Bergh, S. Swain, P. A. Francis, M. Gnant, F. Perrone, M. M. Regan
Summary: Aromatase inhibitors are more effective than tamoxifen in reducing the risk of breast cancer recurrence in premenopausal women receiving ovarian suppression. The main benefit is observed in the first 4 years of treatment, with no additional benefit or loss of benefit in the following years up to 10.
Article
Oncology
Francesco Pignatti, Ulla Wilking, Douwe Postmus, Nils Wilking, Julio Delgado, Jonas Bergh
Summary: This paper discusses the understanding and measurement of drug value in oncology from the perspectives of different decision makers, including regulators, payers, patients, and clinicians. Although a unique definition capturing the concept of value is unlikely to emerge, the importance of understanding different viewpoints and how regulators can help inform different decision makers is discussed.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Caroline Boman, Luisa Edman Kessler, Jonas Bergh, Alexios Matikas, Theodoros Foukakis
Summary: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement. A population-based retrospective study identified characteristics of patients with very short survival time following MBC diagnosis.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Biology
Haomin Yang, Nirmala Bhoo-Pathy, Judith S. Brand, Elham Hedayati, Felix Grassmann, Erwei Zeng, Jonas Bergh, Weiwei Bian, Jonas F. Ludvigsson, Per Hall, Kamila Czene
Summary: Breast cancer patients may have increased risks of arrhythmia, heart failure, and ischemic heart disease after treatment. Specific treatments and drugs are associated with these risks.
Review
Oncology
Evangelos Tzoras, Ioannis Zerdes, Nikos Tsiknakis, Georgios C. Manikis, Artur Mezheyeuski, Jonas Bergh, Alexios Matikas, Theodoros Foukakis
Summary: The evaluation of breast cancer immune microenvironment is important in clinical practice, but the spatiotemporal organization of the anti-breast cancer immune response is not fully explored yet. Multiplex in situ methods with spectral imaging can deconvolute the different elements of tumor immune microenvironment and provide valuable information for classification and biomarker discovery. These methods enable the simultaneous evaluation of multiple targets and characterization of spatial organization of the tumor immune microenvironment.
Correction
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Article
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Summary: This article presents the implementation of the Molecular Tumor Board Portal, a system that integrates and interprets genomics and clinical data to support clinical decision-making in precision oncology. The system automates the interpretation and reporting of sequencing results, reducing errors and promoting consistent decision-making and data capture. It also facilitates collaborative discussion through information-rich patient reports and interactive content.
Review
Oncology
Renske Altena, Laila Hubbert, Narsis A. Kiani, Yvonne Wengstrom, Jonas Bergh, Elham Hedayati
Summary: There is currently a lack of definitive evidence supporting pre-treatment strategies for predicting and preventing cardiovascular disease in cancer patients. More research is needed to determine the best approaches for optimizing health-related outcomes in this population.
Article
Oncology
J. Bergh, K. Pritchard, S. Swain, D. Cameron, K. Albain, S. Anderson, R. Arriagada, J. Bartlett, E. Bergsten-Nordstrom, J. Bliss, R. Bradley, E. Brain, J. Braybrooke, L. Carey, M. Clarke, R. Coleman, J. Cuzick, N. Davidson, L. Del Mastro, A. Di Leo, J. Dignam, D. Dodwell, M. Dowsett, F. Duane, B. Ejlertsen, P. Francis, R. Gelber, M. Gnant, M. Goetz, P. Goodwin, R. Gray, P. Halpin-Murphy, D. Hayes, C. Hill, R. Jagsi, W. Janni, Z. Liu, S. Loibl, E. MacKinnon, E. Mamounas, G. Mannu, M. Martin, P. McGale, H. Mukai, V Nekljudova, L. Norton, Y. Ohashi, H. Pan, R. Peto, M. Piccart, L. Pierce, P. Poortmans, V Raina, D. Rea, M. Regan, J. Robertson, E. Rutgers, D. Slamon, T. Spanic, J. Sparano, G. Steger, C. Taylor, G. Tang, M. Toi, A. Tutt, G. Viale, X. Wang, T. Whelan, N. Wilcken, N. Wolmark
Summary: The study demonstrates that adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer significantly reduces the risk of breast cancer recurrence and death, with worthwhile proportional reductions irrespective of recorded patient and tumor characteristics.
Article
Oncology
David Jaraj, Jonas Hoijer, Linnea Widman, Johan Ahlgren, Lars-Gunnar Arnesson, Zakaria Einbeigi, Marie Klintman, Eva Vikhe Patil, Malin Sund, Irma Fredriksson, Jonas Bergh, Pettersson Andreas
Summary: This study found that the risk of breast cancer death in patients with T1abN0 disease continues to increase steadily and has improved over time, varying substantially by tumor characteristics.
JNCI CANCER SPECTRUM
(2021)